Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Triple Negative Breast Neoplasms × apatinib × Clear all

Phase

Phase 2 8 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Stomach Neoplasms 4 Advanced Gastric Cancer 3 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 Respiratory Tract Diseases 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Lung Diseases 1 Locally Advanced or Metastatic Gastric Adenocarcinoma 1 Liver Neoplasms 1 Hepatic Metastasis of Colorectal Cancer 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Colorectal Cancer Recurrent 1 Biliary Tract Neoplasms 1 Advanced Triple Negative Breast Cancer 1

Interventions

pembrolizumab 30 Nivolumab 14 Paclitaxel 13 Carboplatin 13 Cyclophosphamide 9 sacituzumab govitecan 7 Cisplatin 7 Capecitabine 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 camrelizumab 4 atezolizumab 4 Specimen Handling 4 Ipilimumab 4 Interleukin-2 4 Injections 4 Immune Checkpoint Inhibitors 4 Gemcitabine 4 Docetaxel 4 toripalimab 3 talazoparib 3 fludarabine 3 avelumab 3 Immunoglobulin G 3 Everolimus 3 Clinical Trials, Phase II as Topic 3 spartalizumab 2 seviteronel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡